Illumina, Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 1,250 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.55, for a total transaction of $283,187.50. Following the completion of the sale, the director now owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Illumina, Inc. (NASDAQ ILMN) traded down $2.39 during midday trading on Tuesday, reaching $211.06. 1,050,098 shares of the company’s stock traded hands, compared to its average volume of 958,333. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. The firm has a market cap of $32,885.04, a price-to-earnings ratio of 65.86, a price-to-earnings-growth ratio of 3.72 and a beta of 0.79. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $230.72.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business’s quarterly revenue was up 17.6% on a year-over-year basis. During the same period last year, the business posted $0.97 EPS. sell-side analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current year.

Several institutional investors have recently modified their holdings of ILMN. Daiwa Securities Group Inc. lifted its holdings in Illumina by 3.9% during the 2nd quarter. Daiwa Securities Group Inc. now owns 4,260 shares of the life sciences company’s stock valued at $739,000 after purchasing an additional 160 shares during the last quarter. Korea Investment CORP lifted its holdings in Illumina by 427.3% during the 2nd quarter. Korea Investment CORP now owns 35,663 shares of the life sciences company’s stock valued at $6,188,000 after purchasing an additional 28,900 shares during the last quarter. Pictet Asset Management Ltd. lifted its holdings in Illumina by 3.7% during the 2nd quarter. Pictet Asset Management Ltd. now owns 309,765 shares of the life sciences company’s stock valued at $54,940,000 after purchasing an additional 11,036 shares during the last quarter. Advisor Partners LLC lifted its holdings in Illumina by 10.5% during the 2nd quarter. Advisor Partners LLC now owns 2,449 shares of the life sciences company’s stock valued at $425,000 after purchasing an additional 232 shares during the last quarter. Finally, Seven Bridges Advisors LLC lifted its holdings in Illumina by 17.6% during the 2nd quarter. Seven Bridges Advisors LLC now owns 2,630 shares of the life sciences company’s stock valued at $456,000 after purchasing an additional 393 shares during the last quarter. Institutional investors and hedge funds own 91.75% of the company’s stock.

A number of research firms have recently weighed in on ILMN. Barclays restated an “equal weight” rating and set a $150.00 price target on shares of Illumina in a report on Wednesday, August 9th. Vetr upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 price target on the stock in a report on Wednesday, August 9th. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Goldman Sachs Group restated a “neutral” rating and set a $200.00 price target on shares of Illumina in a report on Tuesday, September 26th. Finally, Canaccord Genuity restated a “buy” rating and set a $230.00 price target (up previously from $215.00) on shares of Illumina in a report on Thursday, October 12th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $201.98.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/05/robert-s-epstein-sells-1250-shares-of-illumina-inc-ilmn-stock.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.